(BBNX) Beta Bionics, Common Stock - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 527m USD | Total Return: -21.6% in 12m
Avg Turnover: 7.12M
Qual. Beats: 0
Rev. Trend: 94.6%
Warnings
Share dilution 41.9% YoY
Interest Coverage Ratio -3.5 is critical
Altman Z'' -13.37 < 1.0 - financial distress zone
Extended 1w
Tailwinds
No distinct edge detected
Beta Bionics, Inc. is a commercial-stage medical technology company specializing in automated insulin delivery systems for patients with type 1 and type 2 diabetes. Its primary product, the iLet Bionic Pancreas, is FDA-cleared for patients aged six and older, utilizing algorithms to automate dosing without the need for traditional manual carb counting. The company is currently expanding its pipeline to include a tubeless patch pump and a bihormonal system that integrates both insulin and glucagon delivery.
The medical device sector in the diabetes space is characterized by high barriers to entry due to rigorous clinical trial requirements and the need for continuous integration with third-party continuous glucose monitors (CGM). Beta Bionics maintains strategic partnerships with Abbott Diabetes Care and Xeris Pharmaceuticals to facilitate these technical integrations and drug formulations. This business model relies on a recurring revenue stream through the sale of durable pump hardware and compatible disposable components.
Investors can evaluate the long-term growth potential and competitive positioning of BBNX by reviewing the comprehensive data available on ValueRay. The company remains focused on scaling its commercial infrastructure and expanding the clinical indications for its automated platforms.
- iLet Bionic Pancreas adoption rates drive quarterly revenue and market share growth
- Regulatory clearance of Bihormonal iLet system impacts long-term valuation and pipeline
- Abbott partnership for integrated CGM technology expands total addressable market reach
- High R&D expenditure for Patch Pump development pressures near-term operating margins
- Insurance reimbursement coverage levels dictate patient access and device sales volume
| Net Income: -66.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.20 > 0.02 and ΔFCF/TA -2.50 > 1.0 |
| NWC/Revenue: 203.9% < 20% (prev 351.5%; Δ -147.5% < -1%) |
| CFO/TA -0.18 > 3% & CFO -54.8m > Net Income -66.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.4m) vs 12m ago 44.67% < -2% |
| Gross Margin: 57.15% > 18% (prev 0.54%; Δ 5.66k% > 0.5%) |
| Asset Turnover: 34.32% > 50% (prev 20.66%; Δ 13.66% > 0%) |
| Interest Coverage Ratio: -3.53 > 6 (EBITDA TTM -74.1m / Interest Expense TTM 21.9m) |
| A: 0.74 (Total Current Assets 248.0m - Total Current Liabilities 23.2m) / Total Assets 304.4m |
| B: -1.29 (Retained Earnings -391.8m / Total Assets 304.4m) |
| C: -0.24 (EBIT TTM -77.3m / Avg Total Assets 321.2m) |
| D: -11.81 (Book Value of Equity -391.9m / Total Liabilities 33.2m) |
| Altman-Z'' = -13.37 = D |
| DSRI: 1.03 (Receivables 17.9m/11.0m, Revenue 110.2m/69.8m) |
| GMI: 0.94 (GM 57.15% / 53.93%) |
| AQI: 0.69 (AQ_t 0.13 / AQ_t-1 0.19) |
| SGI: 1.58 (Revenue 110.2m / 69.8m) |
| TATA: -0.04 (NI -66.4m - CFO -54.8m) / TA 304.4m) |
| Beneish M = -2.86 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 11.72 with a total of 764,049 shares traded.
Over the past week, the price has changed by +24.68%,
over one month by +10.05%,
over three months by -9.98% and
over the past year by -21.61%.
Beta Bionics, Common Stock has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy BBNX.
- StrongBuy: 4
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 19.4 | 65.2% |
P/S = 4.778
P/B = 1.9419
Revenue TTM = 110.2m USD
EBIT TTM = -77.3m USD
EBITDA TTM = -74.1m USD
Long Term Debt = 5.07m USD (estimated: total debt 6.91m - short term 1.84m)
Short Term Debt = 1.84m USD (from shortTermDebt, last quarter)
Debt = 6.91m USD (from shortLongTermDebtTotal, last quarter) (leases 6.91m already included)
Net Debt = -192.6m USD (calculated: Debt 6.91m - CCE 199.5m)
Enterprise Value = 334.1m USD (526.7m + Debt 6.91m - CCE 199.5m)
Interest Coverage Ratio = -3.53 (Ebit TTM -77.3m / Interest Expense TTM 21.9m)
EV/FCF = -5.47x (Enterprise Value 334.1m / FCF TTM -61.1m)
FCF Yield = -18.29% (FCF TTM -61.1m / Enterprise Value 334.1m)
FCF Margin = -55.45% (FCF TTM -61.1m / Revenue TTM 110.2m)
Net Margin = -60.27% (Net Income TTM -66.4m / Revenue TTM 110.2m)
Gross Margin = 57.15% ((Revenue TTM 110.2m - Cost of Revenue TTM 47.2m) / Revenue TTM)
Gross Margin QoQ = 59.50% (prev 58.98%)
Tobins Q-Ratio = 1.10 (Enterprise Value 334.1m / Total Assets 304.4m)
Interest Expense / Debt = 316.8% (Interest Expense 21.9m / Debt 6.91m)
Taxrate = 21.0% (US default 21%)
NOPAT = -61.1m (EBIT -77.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.69 (Total Current Assets 248.0m / Total Current Liabilities 23.2m)
Debt / Equity = 0.03 (Debt 6.91m / totalStockholderEquity, last quarter 271.2m)
Debt / EBITDA = 2.60 (negative EBITDA) (Net Debt -192.6m / EBITDA -74.1m)
Debt / FCF = 3.15 (negative FCF - burning cash) (Net Debt -192.6m / FCF TTM -61.1m)
Total Stockholder Equity = 288.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.68% (Net Income -66.4m / Total Assets 304.4m)
RoE = -9.76% (Net Income TTM -66.4m / Total Stockholder Equity 680.6m)
RoCE = -11.27% (EBIT -77.3m / Capital Employed (Equity 680.6m + L.T.Debt 5.07m))
RoIC = -21.58% (negative operating profit) (NOPAT -61.1m / Invested Capital 283.1m)
WACC = 14.07% (E(526.7m)/V(533.6m) * Re(14.25%) + (debt cost/tax rate unavailable))
Discount Rate = 14.25% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 84.14 | Cagr: 170.8%
[DCF] Fair Price = unknown (Cash Flow -61.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.04 | # QB: 0
Revenue Correlation: 94.60 | Revenue CAGR: 189.1% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.55 | Chg30d=-19.50% | Revisions=-20% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.53 | Chg30d=-19.03% | Revisions=-20% | Analysts=3
EPS current Year (2026-12-31): EPS=-2.11 | Chg30d=-18.85% | Revisions=-20% | GrowthEPS=-52.9% | GrowthRev=+33.3%
EPS next Year (2027-12-31): EPS=-2.39 | Chg30d=-23.32% | Revisions=-20% | GrowthEPS=-13.5% | GrowthRev=+35.0%
[Analyst] Revisions Ratio: -20%